Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:48 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Research and development | $3.47M | $3.44M | $7.87M | $9.07M | $6.75M |
| Selling, general and administrative | $3.74M | $4.16M | $5.44M | $5.52M | $6.42M |
| Operating income | -$9.85M | -$10.2M | -$17.1M | -$15.3M | -$28.8M |
| Net income | -$11.6M | -$23.4M | -$4.00M | -$15.2M | -$29.9M |
| EPS, basic | $-8.66 | $-11.15 | $-5.33 | $-0.39 | – |
| EPS, diluted | $-8.66 | $-11.15 | $-5.33 | – | – |
| Weighted shares, basic | 1.73M | 2.44M | 1.54M | 38.8M | – |
| Weighted shares, diluted | 1.73M | 2.44M | 1.54M | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025! | FY2024! | FY2023! | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | $987.0K | $173.2K | $2.68M | $749.1K | $556.0K |
| Short-term investments | $14.8M | $8.35M | $2.24M | $4.09M | $11.0M |
| Total current assets | $16.6M | $9.41M | $5.82M | $5.40M | $12.7M |
| Goodwill | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M |
| Intangible assets | $14.1M | – | – | – | – |
| Total assets | $41.2M | $21.4M | $17.9M | $17.5M | $24.8M |
| Accounts payable | $2.45M | $2.90M | $3.72M | $2.67M | $986.6K |
| Total current liabilities | $5.53M | $6.70M | $4.99M | $2.77M | $1.04M |
| Total liabilities | $16.4M | $6.70M | $5.09M | $2.84M | $1.17M |
| Shareholders' equity | $21.8M | $9.79M | $12.4M | $14.7M | $23.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | -$9.07M | -$8.98M | -$13.0M | -$12.3M | -$19.5M |
| Capital expenditures | $1.75M | – | – | – | – |
| Free cash flow | -$10.8M | – | – | – | – |
| Stock-based compensation | $2.17M | $1.06M | $3.05M | $695.2K | $90.0K |
| Investing cash flow | -$8.42M | -$6.10M | $1.85M | $6.91M | $19.9M |
| Financing cash flow | $18.3M | $12.6M | $13.1M | $5.55M | $73.5K |
| Net change in cash | $813.8K | -$2.51M | $1.93M | $193.1K | $407.7K |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 12, 2026 | 8.19M | −95.4% | SEC |
| May 15, 2026 | 7.85M | −44.6% | SEC |
| Apr 27, 2026 | 7.85M | −44.6% | SEC |
| Apr 12, 2026 | 7.85M | −22.5% | SEC |
| Nov 17, 2025 | 4.17M | +51.2% | SEC |
| Aug 18, 2025 | 176.6M | +7,350.8% | SEC |
| May 13, 2025 | 14.2M | +514.7% | SEC |
| Apr 4, 2025 | 10.1M | +369.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-30 in Q1 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.